• 1
    Global Initiative for Asthma (GINA), National Institute of Health, National Heart Lung and Blood Institute (NHLBI) / World Health Organisation (WHO). Global strategy for asthma management and prevention. 2012. Workshop Report, updated 2011. Available at (last accessed 15 May 2012). Ref Type: Generic.
  • 2
    Alan & Hanbury Ltd. Seretide Summary of Product Characteristics; Symbicort Summary of Product Characteristics. 2012. Available at (last accessed 15 May 2012). Ref Type: Generic.
  • 3
    Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; (4)CD005533.
  • 4
    European Medicines Agency (EMEA). Guideline on the Investigation of Bioequivalence. 2012. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** – EMA – 2010. Ref Type: Generic.
  • 5
    Jones B, Kenward M. Design and Analysis of Cross-Over Trials, 2nd edn. London: Chapman and Hall, 2003.
  • 6
    Kennaway DJ, Royles P. Circadian rhythms of 6-sulphatoxy melatonin, cortisol and electrolyte excretion at the summer and winter solstices in normal men and women. Acta Endocrinol (Copenh) 1986; 113: 450456.
  • 7
    Piccinno A, Poli G, Acerbi D, Burton I, Druart X. Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and Formoterol CFC-free fixed combination in healthy volunteers. 2007. Poster presented at the European Respiratory Society, Stockholm, Sweden. Ref Type: Abstract.
  • 8
    Poli G, Collarini S, Acerbi D, Fantini M, Usberti F, De Decker M. Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus Formoterol Fixed Combination. 2010. Poster presented at the European Respiratory Society, Barcelona, Spain. Ref Type: Abstract.
  • 9
    van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (Part 2): clinical experience in children. Int J Clin Pract 2004; 58: 786794.
  • 10
    Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD, O'Dowd L. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy Asthma Proc 2010; 31: 2639.
  • 11
    Eid NS, Noonan MJ, Chipps B, Parasuraman B, Miller CJ, O'Brien CD. Once- vs twice-daily budesonide/formoterol in 6 to 15-year-old patients with stable asthma. Pediatrics 2010; 126: e565e575.
  • 12
    Pearlman DS, Kottakis J, Till D, Della CG. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr Med Res Opin 2002; 18: 445455.